GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vilin Bio Med Ltd (NSE:VILINBIO) » Definitions » Asset Turnover

Vilin Bio Med (NSE:VILINBIO) Asset Turnover : 0.25 (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Vilin Bio Med Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Vilin Bio Med's Revenue for the six months ended in Sep. 2023 was ₹76.46 Mil. Vilin Bio Med's Total Assets for the quarter that ended in Sep. 2023 was ₹309.44 Mil. Therefore, Vilin Bio Med's Asset Turnover for the quarter that ended in Sep. 2023 was 0.25.

Asset Turnover is linked to ROE % through Du Pont Formula. Vilin Bio Med's annualized ROE % for the quarter that ended in Sep. 2023 was 6.56%. It is also linked to ROA % through Du Pont Formula. Vilin Bio Med's annualized ROA % for the quarter that ended in Sep. 2023 was 4.97%.


Vilin Bio Med Asset Turnover Historical Data

The historical data trend for Vilin Bio Med's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vilin Bio Med Asset Turnover Chart

Vilin Bio Med Annual Data
Trend Mar20 Mar21 Mar22
Asset Turnover
1.20 0.84 0.82

Vilin Bio Med Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Sep23
Asset Turnover - - - 0.30 0.25

Competitive Comparison of Vilin Bio Med's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vilin Bio Med's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Vilin Bio Med's Asset Turnover falls into.



Vilin Bio Med Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Vilin Bio Med's Asset Turnover for the fiscal year that ended in Mar. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2022 )/( (Total Assets (A: Mar. 2021 )+Total Assets (A: Mar. 2022 ))/ count )
=112.149/( (138.914+135.583)/ 2 )
=112.149/137.2485
=0.82

Vilin Bio Med's Asset Turnover for the quarter that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2023 )/( (Total Assets (Q: Sep. 2022 )+Total Assets (Q: Sep. 2023 ))/ count )
=76.457/( (0+309.444)/ 1 )
=76.457/309.444
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Vilin Bio Med  (NSE:VILINBIO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Vilin Bio Med's annulized ROE % for the quarter that ended in Sep. 2023 is

ROE %**(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=15.382/234.467
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(15.382 / 152.914)*(152.914 / 309.444)*(309.444/ 234.467)
=Net Margin %*Asset Turnover*Equity Multiplier
=10.06 %*0.4942*1.3198
=ROA %*Equity Multiplier
=4.97 %*1.3198
=6.56 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2023) net income data. The Revenue data used here is two times the semi-annual (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Vilin Bio Med's annulized ROA % for the quarter that ended in Sep. 2023 is

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=15.382/309.444
=(Net Income / Revenue)*(Revenue / Total Assets)
=(15.382 / 152.914)*(152.914 / 309.444)
=Net Margin %*Asset Turnover
=10.06 %*0.4942
=4.97 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2023) net income data. The Revenue data used here is two times the semi-annual (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Vilin Bio Med Asset Turnover Related Terms

Thank you for viewing the detailed overview of Vilin Bio Med's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Vilin Bio Med (NSE:VILINBIO) Business Description

Traded in Other Exchanges
N/A
Address
Opposite Sub Registrar’s Office, Survey No.115/GF/J, Hanumanji Colony, Bowempally, Secunderabad, TG, IND, 500009
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules & Nutritional Food supplements.

Vilin Bio Med (NSE:VILINBIO) Headlines

No Headlines